Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia

Leukemia Research

Volumn 33, Issue 2, 2009, Pages 336-339

  Valle, Mariela ^a   Plon, Sharon E ^a   Rabin, Karen R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukemia; Clonogenic survival assay; Down syndrome; MTT assay

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; DOXORUBICIN; MAFOSFAMIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOWN SYNDROME; DRUG SENSITIVITY; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOBLASTOID CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CHILD; DOWN SYNDROME; FIBROBLASTS; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 56949088952     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.07.011     Document Type: Article

References (11)

1. Whitlock J.A. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol 135 5 (December) (2006) 595-602
2. Taub J.W., and Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer 44 1 (January) (2005) 33-39
3. Gamis A.S. Acute myeloid leukemia and Down syndrome evolution of modern therapy-state of the art review. Pediatr Blood Cancer 44 1 (January) (2005) 13-20
4. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 1-2 (December) (1983) 55-63
5. Horton T.M., Gannavarapu A., Blaney S.M., D'Argenio D.Z., Plon S.E., and Berg S.L. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 58 1 (July) (2006) 13-23
6. Hisama F.M., Chen Y.H., Meyn M.S., Oshima J., and Weissman S.M. WRN or telomerase constructs reverse 4-nitroquinoline 1-oxide sensitivity in transformed Werner syndrome fibroblasts. Cancer Res 60 9 (May) (2000) 2372-2376
7. Munshi A., Hobbs M., and Meyn R.E. Clonogenic cell survival assay. In: Blumenthal R.D. (Ed). Methods in molecular medicine (2005), Humana Press, Totowa (NJ) 21-28
8. Zwaan C.M., Kaspers G.J., Pieters R., Hahlen K., Janka-Schaub G.E., Van Zantwijk C.H., et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 99 1 (January) (2002) 245-251
9. Frost B.M., Gustafsson G., Larsson R., Nygren P., and Lonnerholm G. Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome?. Leukemia 14 5 (May) (2000) 943-944
10. Ugazio A.G., Maccario R., Notarangelo L.D., and Burgio G.R. Immunology of Down syndrome: a review. Am J Med Genet Suppl 7 (1990) 204-212
11. Sommer C.A., Pavarino-Bertelli E.C., Goloni-Bertollo E.M., and Henrique-Silva F. Identification of dysregulated genes in lymphocytes from children with Down syndrome. Genome 51 1 (January) (2008) 19-29